Phase 2 N=42 Pembrolizumab and GM-CSF in Biliary Cancer
Biliary Cancer
Primary: Overall Response Rate (ORR) — 0.12 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=59 Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children
Migraine
Primary: Change in Pain Score After Analgesic Administration (Faces Pain Scale - Revised (FPS-R) — 4.2; 4.4 units on a scale
Phase 1 N=23 A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Opioid Use Disorder
Primary: Number of Participants With Adverse Events (AEs) — 16; 6; 7; 6 Participants
Phase 2 N=30 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Triple Negative Breast Cancer · Endometrial Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary: Cohort 1 - Progression-free Survival (PFS) — 1.9 Months
Phase 2 N=79 DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Adenocarcinoma Gastric Stage IV With Metastases · Adenocarcinoma - GEJ
Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive…
N/A N=364 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma · Digestive System Diseases · Ovarian Diseases
Primary: Number of Participant Deaths — 56 Participants
Phase 2 N=200 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: 8-Week Disease Control Rate (DCR) — 0; 0; 3; 3 Participants
Phase 2 N=193 Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)
Postsurgical Pain
Primary: Pain Intensity Scores — 367.41; 415.27; 373.92; 447.05 scores on a scale*hours — p=0.0004
N/A N=190 Reducing Tobacco Use Disparities Among Low-Income Adults
Cigarette Smoking · Nicotine Dependence
Primary: Quitline Treatment Engagement — 25; 0 Participants
N/A N=205 RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
Coronary Artery Disease
Primary: Number of Participants With Target Vessel Failure (TVF) — 14 Participants
Phase 2 N=31 Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Waldenstrom's Macroglobulinemia
Primary: Major Response Rate — 26 Participants
Phase 2 N=265 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Multiple Myeloma
Primary: D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR) — 88.1; 90.8; 84.8 percentage of participants
Phase 2 N=40 BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
Covid19
Primary: Number of Serious Adverse Events — 4; 6 Adverse Events
Phase 3 N=2,414 Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
Influenza · Human · Virus Diseases
Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI)…
N/A N=35 Clinical Characterization of an Investigational Soft Silicone Hydrogel Contact Lens
Refractive Errors
Primary: Front Surface Wettability, by Category — 70; 0; 0; 0 eyes